ES3028538T3 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases - Google Patents

5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases Download PDF

Info

Publication number
ES3028538T3
ES3028538T3 ES19742480T ES19742480T ES3028538T3 ES 3028538 T3 ES3028538 T3 ES 3028538T3 ES 19742480 T ES19742480 T ES 19742480T ES 19742480 T ES19742480 T ES 19742480T ES 3028538 T3 ES3028538 T3 ES 3028538T3
Authority
ES
Spain
Prior art keywords
compound
mitochondrial
hydroxyethyl
thiazolidine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19742480T
Other languages
English (en)
Spanish (es)
Inventor
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Pascau Laura Pilar Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Application granted granted Critical
Publication of ES3028538T3 publication Critical patent/ES3028538T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES19742480T 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases Active ES3028538T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382397 2018-06-06
PCT/IB2019/054696 WO2019234664A1 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
ES3028538T3 true ES3028538T3 (en) 2025-06-19

Family

ID=62716008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19742480T Active ES3028538T3 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Country Status (13)

Country Link
US (2) US11957670B2 (enExample)
EP (2) EP3801515B1 (enExample)
JP (1) JP7376934B2 (enExample)
DK (1) DK3801515T3 (enExample)
ES (1) ES3028538T3 (enExample)
FI (1) FI3801515T3 (enExample)
HR (1) HRP20250591T1 (enExample)
HU (1) HUE071482T2 (enExample)
LT (1) LT3801515T (enExample)
PL (1) PL3801515T3 (enExample)
PT (1) PT3801515T (enExample)
SI (1) SI3801515T1 (enExample)
WO (1) WO2019234664A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
EP3917509A4 (en) 2019-01-28 2022-11-09 Mitochondria Emotion, Inc. TRANS-4-HYDROXYCYCLOHEXYLPHENYLAMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
EP3013371A4 (en) 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
US20180364595A1 (en) 2015-09-30 2018-12-20 Nikon Corporation Exposure apparatus, flat panel display manufacturing method, and device manufacturing method
WO2017083739A1 (en) 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN106202285A (zh) 2016-06-30 2016-12-07 北京百度网讯科技有限公司 搜索结果展示方法和装置
MX379710B (es) 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
MX2020013182A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Also Published As

Publication number Publication date
WO2019234664A1 (en) 2019-12-12
JP2021527049A (ja) 2021-10-11
DK3801515T3 (da) 2025-04-28
HUE071482T2 (hu) 2025-08-28
US20210228559A1 (en) 2021-07-29
JP7376934B2 (ja) 2023-11-09
LT3801515T (lt) 2025-06-10
FI3801515T3 (fi) 2025-05-27
PL3801515T3 (pl) 2025-07-14
EP4545142A2 (en) 2025-04-30
EP3801515A1 (en) 2021-04-14
EP4545142A3 (en) 2025-06-11
PT3801515T (pt) 2025-06-11
US11957670B2 (en) 2024-04-16
HRP20250591T1 (hr) 2025-07-04
EP3801515B1 (en) 2025-04-09
SI3801515T1 (sl) 2025-07-31
US20250064791A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
US11427588B2 (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
US20250064791A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
US10793514B2 (en) Glutamine transport inhibitors and methods for treating cancer
ES2993833T3 (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
ES2867300T3 (es) 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-diona para tratamiento de enfermedad de hígado graso no alcohólico
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
ES2973215T3 (es) Agente terapéutico para la esclerosis lateral amiotrófica y composición para el tratamiento
PT2275108E (pt) Preparação farmacêutica que compreende inibidor de dpp-iv e outro agente terapêutico de diabetes na forma concomitante ou combinada
CN113813387A (zh) Ppar激动剂在制备治疗急性髓细胞白血病的药物中的应用
US20080027052A1 (en) Methods for treating cystic kidney disease
US20210308113A1 (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
AU2019247871A1 (en) Compositions and methods for increasing remyelination
WO2020249717A1 (en) Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer
JP5781077B2 (ja) ダウン症を治療するための方法および薬学的組成物
ES2610362T3 (es) Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
JP2009078977A (ja) 心筋の小胞体ストレス抑制剤
WO2023090411A1 (ja) 心疾患または骨格筋の疾患の治療用医薬
CN110869044A (zh) 肽和用肽治疗营养不良相关病症的方法
EA047277B1 (ru) Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона
US20210323949A1 (en) Compounds and methods for inhibition of multiple myeloma
CN121102486A (zh) 含gls1抑制剂和ampk激活剂的药物组合物及其用途
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト
BR102016021058A2 (pt) composições de compostos orgânicos de selênio e métodos de uso das mesmas